MNMD

Mind Medicine (MindMed) Inc. [MNMD] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

MNMD Stock Summary

Top MNMD Correlated Resources

MNMD


Top 10 Correlated ETFs

MNMD


Top 10 Correlated Stocks

MNMD


In the News

02:46 29 Mar 2024 MNMD

PLTR, MNMD, ODD: Finding Value in the Market

Hilary Kramer discusses finding value in the market. She talks about her stock picks which include Palantir (PLTR), Mind Medicine (MNMD), Oddity (ODD), Prairie Operating (PROP), Starbucks (SBUX), and Arm Holdings (ARM).

11:50 29 Mar 2024 MNMD

MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag

The FDA bestows a breakthrough therapy designation to MindMed's (MNMD) MM120 for treating generalized anxiety disorder. Shares rise more than 50% on the news.

03:31 29 Mar 2024 MNMD

Psychedelics stocks fly as FDA recognizes Mind Medicine's LSD drug as breakthrough therapy

Psychedelics stocks traded higher on Thursday as investor optimism returned to the sector on the news that MindMed (NASDAQ:MNMD, NEO:MMED)'s LSD drug candidate was granted breakthrough therapy status by the US Food and Drug Administration (FDA) for the treatment of generalized anxiety disorder (GAD).  Shares of MindMed (NASDAQ:MNMD, NEO:MMED) led the charge, gaining 54% at US$9.15 in the mid-afternoon.

09:37 29 Mar 2024 MNMD

Why Is MindMed (MNMD) Stock Up 32% Today?

MindMed (NASDAQ: MNMD ) stock is on the rise Thursday after the clinical-stage biopharmaceutical company received breakthrough therapy designation from the Food and Drug Administration (FDA). This designation covers the company's MM120 program in development to treat generalized anxiety disorder.

09:19 29 Mar 2024 MNMD

Mind Medicine's LSD drug candidate awarded FDA breakthrough therapy designation; shares soar

MindMed (NASDAQ:MNMD, NEO:MMED) shares soared more than 26% higher before Thursday's opening bell after the biopharmaceutical firm revealed that its drug candidate MM120 has been awarded breakthrough therapy status from the US Food and Drug Administration (FDA) for the treatment of generalized anxiety disorder (GAD). MM120 is the tartrate sale form of lysergide (LSD) being developed by MindMed (NASDAQ:MNMD, NEO:MMED) for GAD and other potential applications in brain health disorders.

09:00 29 Mar 2024 MNMD

MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a conference call and webcast on March 7, 2024. The program will provide an update on MM120 in Generalized Anxiety Disorder (GAD), including 12-week topline safety, efficacy, and durability results from the Company's Phase 2b tria.

04:50 29 Mar 2024 MNMD

Why Is MindMed (MNMD) Stock Up 8% Today?

A positive news update for Mind Medicine (NASDAQ: MNMD ) is elevating the entire psychedelic treatment sector today. Specifically, the U.S. Food and Drug Administration (FDA) has just granted midomafetamine capsules (MDMA) a priority review.

12:00 29 Mar 2024 MNMD

De-Risking Psychedelics: Compass Pathways, Cybin And Atai

Critical catalysts are approaching in the psychedelic sector, with the potential for the first FDA-approved psychedelic therapy by the end of the year.

01:31 29 Mar 2024 MNMD

What Makes Mind Medicine (MindMed) Inc. (MNMD) a New Buy Stock

Mind Medicine (MindMed) Inc. (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

10:16 29 Mar 2024 MNMD

Mind Medicine's MM-120 shows promise in Phase 2b trial for Generalized Anxiety Disorder

Mind Medicine (MindMed (NASDAQ:MNMD, NEO:MMED)) has announced encouraging results from its Phase 2b clinical trial of MM-120 in treating Generalized Anxiety Disorder (GAD). MM-120, a single-dose lysergide d-tartrate, demonstrated statistically significant and clinically meaningful improvements over placebo at Week 4, meeting its primary endpoint.

MNMD Financial details

Company Rating
Neutral
Market Cap
404.25M
Income
-98.4M
Revenue
0
Book val./share
1.94
Cash/share
2.48
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-2.44
Forward P/E
-6.57
PEG
-0.38
P/S
-
P/B
1.79
P/C
3.79
P/FCF
-4.47
Quick Ratio
3.78
Current Ratio
3.85
Debt / Equity
0.18
LT Debt / Equity
0.18
-
-
EPS (TTM)
-2.52
EPS next Y
-1.43
EPS next Q
-0.42
EPS this Y
59.48%
EPS next Y
-43.25%
EPS next 5Y
-149.13%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
31.11%
-
-
-
-
SMA20
66.67%
SMA50
150%
SMA100
233.33%
Inst Own
0%
Inst Trans
0.99%
ROA
-50%
ROE
-58%
ROC
-0.8%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
70.5M
Shs Float
67.73M
-
-
-
-
Target Price
5
52W Range
2.41-11.1
52W High
-14.55%
52W Low
+370%
RSI
63
Rel Volume
1.18
Avg Volume
1.83M
Volume
2.15M
Perf Week
-3.69%
Perf Month
91.06%
Perf Quarter
216.5%
Perf Half Y
159.67%
-
-
-
-
Beta
2.462
-
-
Volatility
0.35%, 2%
Prev Close
0%
Price
9.4
Change
-1.05%

MNMD Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-08-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-2.94-1.92-3.4-1.53-2.44
Operating cash flow per share
-0.55-1.33-1.67-1.62-1.64
Free cash flow per share
-1.37-1.33-1.67-1.62-1.64
Cash per share
0.054.514.884.612.55
Book value per share
7.224.275.544.892
Tangible book value per share
7.224.274.564.131.47
Share holders equity per share
7.224.275.544.892
Interest debt per share
00.010.010.050.36
Market cap
267.48K811.97M566.71M67.89M143.32M
Enterprise value
249.55K731.88M433.17M-74.18M57.74M
P/E ratio
-0.24-23.81-6.09-1.44-1.5
Price to sales ratio
00000
POCF ratio
-1.29-34.41-12.37-1.35-2.23
PFCF ratio
-0.51-34.41-12.37-1.35-2.23
P/B Ratio
0.110.73.740.451.83
PTB ratio
0.110.73.740.451.83
EV to sales
00000
Enterprise value over EBITDA
-0.54-22.16-4.621-0.64
EV to operating cash flow
-1.2-31.02-9.451.48-0.9
EV to free cash flow
-0.48-31.02-9.451.48-0.9
Earnings yield
-4.17-0.04-0.16-0.7-0.67
Free cash flow yield
-1.95-0.03-0.08-0.74-0.45
Debt to equity
00000.18
Debt to assets
00000.11
Net debt to EBITDA
0.042.421.421.910.94
Current ratio
14.7627.113.188.163.22
Interest coverage
0-201.4-268.42-44.370
Income quality
0.190.70.490.880.67
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
000.160.140.16
Capex to operating cash flow
1.510000
Capex to revenue
00000
Capex to depreciation
-46.90000
Stock based compensation to revenue
00000
Graham number
21.8513.5920.5812.9810.48
ROIC
-0.17-0.44-0.63-0.37-1.02
Return on tangible assets
-0.38-0.42-0.68-0.32-0.92
Graham Net
-0.474.194.433.991.36
Working capital
2.74M78.51M126.81M128.16M71.63M
Tangible asset value
2.74M75.87M124.88M127.31M57.69M
Net current asset value
2.74M75.87M124.88M126.98M57.47M
Invested capital
00000.18
Average receivables
02.54K000
Average payables
01.01M3.1M3.14M3.12M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00582.94239.07477.43
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
000.631.530.76
Inventory turnover
-792.97K0000
ROE
-0.41-0.45-0.61-0.31-1.23
Capex per share
-0.830000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
0.13-0.72-0.76-0.45-0.59
Operating cash flow per share
-0.42-0.35-0.36-0.42-0.49
Free cash flow per share
-0.42-0.35-0.36-0.42-0.49
Cash per share
4.613.43.032.962.48
Book value per share
4.893.422.752.421.94
Tangible book value per share
4.132.822.181.881.43
Share holders equity per share
4.893.422.752.421.94
Interest debt per share
0.040.0400.350.35
Market cap
67.89M120.7M137.72M124.32M147.42M
Enterprise value
-74.18M-8.63M20.9M20.69M61.85M
P/E ratio
4.15-1.1-1.18-1.73-1.54
Price to sales ratio
00000
POCF ratio
-5.28-9.05-9.95-7.48-7.45
PFCF ratio
-5.28-9.05-9.95-7.48-7.45
P/B Ratio
0.450.931.31.31.89
PTB ratio
0.450.931.31.31.89
EV to sales
00000
Enterprise value over EBITDA
3.520.41-0.77-0.96-2.89
EV to operating cash flow
5.770.65-1.51-1.24-3.12
EV to free cash flow
5.770.65-1.51-1.24-3.12
Earnings yield
0.06-0.23-0.21-0.14-0.16
Free cash flow yield
-0.19-0.11-0.1-0.13-0.13
Debt to equity
0000.150.18
Debt to assets
0000.10.11
Net debt to EBITDA
6.756.24.34.794
Current ratio
8.165.53.413.853.22
Interest coverage
-13.21-18.33000
Income quality
2.620.540.480.930.83
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.140.150.160.150.16
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
3.827.466.834.955.09
ROIC
0.08-0.2-0.27-0.19-0.24
Return on tangible assets
0.03-0.21-0.24-0.15-0.23
Graham Net
3.992.742.091.821.32
Working capital
128.16M108.32M84.67M88.93M71.63M
Tangible asset value
127.31M107.53M83.95M74.74M57.69M
Net current asset value
126.98M107.23M83.68M74.52M57.47M
Invested capital
0000.150.18
Average receivables
00000
Average payables
1.47M2.22M5.45M8.13M5.91M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
236.6259.38948.32864.68471.19
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.380.350.090.10.19
Inventory turnover
00000
ROE
0.03-0.21-0.27-0.19-0.31
Capex per share
00000

MNMD Frequently Asked Questions

What is Mind Medicine (MindMed) Inc. stock symbol ?

Mind Medicine (MindMed) Inc. is a CA stock , located in Vancouver of Bc and trading under the symbol MNMD

Is Mind Medicine (MindMed) Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $5. The lowest prediction is $5 and the highest is $5

What is MNMD stock prediction ?

What is Mind Medicine (MindMed) Inc. stock quote today ?

Mind Medicine (MindMed) Inc. stock price is $9.4 today.

Is Mind Medicine (MindMed) Inc. stock public?

Yes, Mind Medicine (MindMed) Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap